Italy’s Menarini Group has formed a strategic partnership with China-based precision medicine firm OrigiMed to co-develop a pan-cancer single-cell molecular diagnostic innovation platform. The collaboration leverages the respective platform advantages and integrates resources to work on a single-cell clinical molecular diagnosis project based on high-throughput next-generation sequencing technology. Moving forward, the two sides will collaborate in the area of tumor precision diagnosis and treatment. Financial details of the partnership were not disclosed.
Company Overviews and Expertise
Menarini Group is focused on the R&D, production, and sales of rare cell separation systems and single-cell molecular analysis reagents. The company provides pharmacological solutions in therapeutic areas such as cardiovascular disease, oncology, pain/inflammation, asthma, and anti-infection. OrigiMed, on the other hand, offers “one-stop” solutions in support of drug development, from biomarker discovery to companion diagnostic development.
Future Outlook
The partnership between Menarini and OrigiMed marks a significant step in advancing single-cell molecular diagnostics for pan-cancer applications. By combining their expertise and resources, the collaboration aims to enhance precision medicine capabilities, ultimately improving patient outcomes through more accurate and personalized diagnostic solutions.-Fineline Info & Tech
